How shall we treat locally advanced triple negative breast cancer?
Keyword(s):
Her 2
◽
Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC
2017 ◽
Vol 35
(15_suppl)
◽
pp. 585-585
◽
2020 ◽
Vol 38
(15_suppl)
◽
pp. e13067-e13067
2013 ◽
Vol 33
(2)
◽
pp. 262-265
◽
2021 ◽
2014 ◽
Vol 10
(01)
◽
pp. 35
◽
2011 ◽
Vol 29
(27_suppl)
◽
pp. 274-274
2017 ◽
Vol 39
◽
pp. 293-296